Gastric Cancer Market Set to Surge to $10.7 Billion by 2031 at a 17.9% CAGR

In 2021, the global gastric cancer market was valued at $2.1 billion. Projections indicate a substantial increase, with expectations to reach $10.7 billion by 2031, reflecting a CAGR of 17.9% from 2022 to 2031. Gastric cancer, commonly referred to as stomach cancer, originates from the cells lining the stomach. Symptoms often include abdominal pain, bloating, nausea, vomiting, and weight loss. The global gastric cancer market has witnessed significant growth in recent years, driven by various factors such as the rising incidence of the disease, advancements in treatment options, and increased awareness about early detection.

Read More: https://www.alliedmarketresearch.com/gastric-cancer-market-A74458

Gastric Cancer Market Growth Factors

Several factors contribute to the rapid expansion of the gastric cancer market:

1. Increasing Incidence of Gastric Cancer: The global rise in gastric cancer cases necessitates effective treatments. Sedentary lifestyles and irregular eating habits have been linked to the disease's prevalence.

2. Lifestyle and Dietary Habits: Diets high in salt, smoked or pickled foods, and low in fruits and vegetables have been associated with an increased risk of gastric cancer. Additionally, smoking remains a significant risk factor, with its prevalence contributing to the disease's occurrence.

3. Aging Population: As the global population ages, the risk of developing gastric cancer increases, particularly among individuals over the age of 50. This demographic shift is anticipated to drive market growth.

4. Advancements in Treatment Options: The development of new therapies, including targeted treatments and immunotherapies, has improved patient outcomes, thereby increasing the demand for innovative treatment options.

5. Increased Awareness and Early Detection: Growing awareness about the risk factors and symptoms of gastric cancer has led to earlier diagnoses, which are crucial for effective treatment and improved survival rates.

Get Sample PDF Copy Here: https://www.alliedmarketresearch.com/request-sample/A74458

Gastric Cancer Market Segmentation

The gastric cancer market is segmented based on disease type, treatment type, drug class outlook, route of administration, and distribution channel.

1. By Disease Type:
- Adenocarcinoma: This is the most common form of gastric cancer, originating in the glandular cells of the stomach lining.
- Gastric Lymphoma: A rare type of cancer that starts in the stomach's lymphatic tissue.
- Others: Includes gastrointestinal stromal tumors and carcinoid tumors.

2. By Treatment Type:
- Chemotherapy: Utilizes drugs to kill cancer cells and is a standard treatment for gastric cancer.
- Targeted Therapy: Involves drugs that target specific genes or proteins to inhibit cancer growth.
- Immunotherapy: Employs the body's immune system to combat cancer cells.
- Radiation Therapy and Surgery: Used to remove or destroy cancerous tissues.

3. By Drug Class Outlook:
- HER2 Antagonists: Target the HER2 protein, which can promote the growth of cancer cells.
- VEGFR2 Antagonists: Inhibit the vascular endothelial growth factor receptor 2, reducing tumor blood supply.
- PD-1/PD-L1 Inhibitors: Enhance the immune system's ability to fight cancer by blocking the PD-1/PD-L1 pathway.

4. By Route of Administration:
- Oral: Medications taken by mouth, offering convenience and ease of use.
- Injectable: Drugs administered via injection, often used for treatments requiring rapid absorption.

5. By Distribution Channel:
- Specialty and Retail Pharmacies: Provide patients with access to medications and support adherence to treatment.
- Hospital Pharmacies: Dispense medications within hospital settings, ensuring immediate availability for inpatients.

Gastric Cancer Market Regional Insights

In 2021, Europe dominated the global gastric cancer market and is projected to remain the fastest-growing region during the forecast period. Factors such as an aging population and lifestyle choices contribute to this trend.

Key Players

The gastric cancer market comprises several key players dedicated to developing effective treatments. Notable companies include:

- Novartis AG
- Pfizer, Inc.
- Mylan N.V.
- F. Hoffmann La Roche Ltd.
- Eli Lilly and Company
- Merck & Co., Inc.
- Teva Pharmaceutical Industries Ltd.
- Celltrion Healthcare Co., Ltd.
- Samsung Bioepis
- Bristol Myers Squibb Company

These companies are at the forefront of research and development, striving to introduce innovative therapies to improve patient outcomes in the gastric cancer market.

The gastric cancer market is experiencing significant growth, driven by increasing disease incidence, lifestyle factors, advancements in treatment options, and heightened awareness leading to early detection. With ongoing research and development, the market is poised to offer more effective and targeted therapies, improving the prognosis for patients diagnosed with gastric cancer.

Procure Complete Report Here: https://www.alliedmarketresearch.com/checkout-final/f2f802e5330c924d05c975ad6b64d9a5?utm_source=NileshMusale

Thanks for reading this article; you can also get an individual chapter-wise sections or region-wise report versions like North America, LATAM, Europe, or Southeast Asia.

Contact Us:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.